Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. Two women will share the Nobel prize for a gene editing technology that will change the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. Registration on or use of this site constitutes acceptance of our Terms of Service and Privacy Policy. Cowen and Company's 40th Annual Health Care Conference. , /PRNewswire/ -- KromaTiD, Inc. today announced the appointment of Vic Myer to its Board of Directors. Investor ContactMark Mullikin(617) 401-9083mark.mullikin@editasmed.com, Media ContactCristi Barnett(617) 401-0113cristi.barnett@editasmed.com, Registration on or use of this site constitutes acceptance of our, A 100-year-old stock indicator just flashed a bullish signal suggesting further market upside », Microsoft told employees it plans to release a browser-based app for the Xbox Game Pass streaming service next year that will get around Apple App Store rules: 'We absolutely will end up on iOS' », CRISPR gene editing discoverers share Nobel Prize, Editas Medicine to Participate in Upcoming Investor Conference, Better Buy: CRISPR Therapeutics vs. Editas Medicine, Pre-market Movers In Healthcare Sector: TLSA, APDN, AVEO, TNXP, ETON…, Editas Medicine Announces U.S. Patent and Trademark Office Grants the Broad Institute Priority Benefit in CRISPR Interference, Editas Medicine to Participate in Upcoming Investor Conferences, Editas Medicine Receives Rare Pediatric Disease Designation for EDIT-301 for the Treatment of Sickle Cell Disease, 5 Disruptive Biotech Stocks to Buy for the Future That Is Here. Weighted-average common shares outstanding, basic and diluted, Cash, cash equivalents, and marketable securities. EDIT-301 is comprised of sickle patient CD34+ cells genetically modified using a highly specific and efficient CRISPR/Cas12a (also known as Cpf1) ribonucleoprotein (RNP) to edit the HBG1/2 promoter region in the beta-globin locus. Futures and Forex: 10 or 15 minute delay, CT. © 2020 Barchart.com, Inc. All Rights Reserved. © 2020 Insider Inc. and finanzen.net GmbH (Imprint). Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. We take a look at earnings estimates for some clues. May 7, 2020 at 8:00 AM EDT Click here for Webcast. Stock quotes by finanzen.net. Chardan Virtual 4th Annual Genetic Medicines Conference, Morgan Stanley 18th Annual Global Healthcare Conference, Wells Fargo 2020 Virtual Healthcare Conference, Citi’s 15th Annual BioPharma Virtual Conference, Q2 2020 Editas Medicine Inc. Earnings Conference Call, Raymond James’ Human Health Innovation Conference, Q1 2020 Editas Medicine Inc. Earnings Conference Call, Cowen and Company's 40th Annual Health Care Conference, Q4 2019 Editas Medicine Inc. Earnings Conference Call, J.P. Morgan 38th Annual Healthcare Conference - Q & A Session. The $4.4 million increase was primarily attributable to fees incurred related to licensing and sublicensing activities, research personnel growth to support our programs as well as our expansion of the development organization and facilities These increases were partially offset by a decrease in process and platform expenses and share-based compensation. Commerce Policy | Except as required by law, the Company explicitly disclaims any obligation to update any forward-looking statements. Location. The increase was largely due to the $203.7 million in net proceeds raised from the company’s recent equity offering. Citi’s 15th Annual BioPharma Conference, September 9-10, Virtual; 2020 Wells Fargo Healthcare Conference, September 9-10, Virtual; and. At Editas Medicine, we are using this technology to develop transformative and durable medicines for people living with serious diseases. About EDIT-301EDIT-301 is an experimental, autologous cell therapy medicine under investigation for the treatment of sickle cell disease. All rights reserved. Editas Medicine to Participate in Upcoming Investor Conferences. The Editas Medicine management team will host a conference call and webcast today at 5:00 p.m. Collaboration and other research and development revenues were $10.7 million for the three months ended June 30, 2020, compared to $2.3 million for the same period in 2019. For the latest information and scientific presentations, please visit www.editasmedicine.com. Editas Medicine plans to participate in the following scientific and medical conferences: Editas Medicine plans to participate in the following investor events: Conference Call The Editas Medicine management team will host a conference call and webcast today at 5:00 p.m. The FDA approves higher dose (60 mg) of BioMarin's (BMRN) Phenylketonuria drug Palynziq injection. About EDIT-201EDIT-201 is an experimental, allogeneic natural killer (NK) cell medicine under investigation for the treatment of solid tumor cancers. Zacks Equity Research - ZACKS - Thu Oct 8, 12:08PM CDT, Kevin Cook - ZACKS - Wed Oct 7, 5:05PM CDT, Zacks Equity Research - ZACKS - Wed Sep 23, 10:03AM CDT, Kevin Cook - ZACKS - Wed Sep 9, 4:26PM CDT, Zacks Equity Research - ZACKS - Sat Sep 5, 10:32AM CDT, Zacks Equity Research - ZACKS - Tue Aug 25, 10:54AM CDT, Zacks Equity Research - ZACKS - Mon Aug 10, 10:54AM CDT, Dividendchannel.com - DVND - Fri Jun 19, 10:34AM CDT. To access the call, please dial (844) 348-3801 (domestic) or (213) 358-0955 (international) and provide the passcode 9185596. Editas (EDIT) reported earnings 30 days ago. CAMBRIDGE, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced it … Made In NYC | Right-click on the chart to open the Interactive Chart menu. To ensure the efficient advancement of our pioneering gene editing medicines, we strengthened our balance sheet with the closing of a common stock offering resulting in gross proceeds of approximately $216 million. About Editas MedicineAs a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Investor ContactMark Mullikin(617) 401-9083mark.mullikin@editasmed.com, Media ContactCristi Barnett(617) 401-0113cristi.barnett@editasmed.com. The biotech holds exclusive rights to CRISPR, a mechanism for cutting and pasting changes to DNA at precise locations. Volume reflects consolidated markets. The words ‘‘anticipate,’’ ‘‘believe,’’ ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ ‘‘intend,’’ ‘‘may,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘target,’’ ‘‘should,’’ ‘‘would,’’ and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced results from a pre-clinical, proof-of-concept study of EDIT-301. Editas Medicine, Inc. (EDIT) CEO Cindy Collins on Q2 2020 Results - Earnings Call Transcript SA Transcripts Thu, Aug. 06 1 Comment Editas Medicine, Inc. 2020 Q2 - Results - … His portfolios have been honored by Marketocracy and Morningstar. Editas Medicine to Participate in Upcoming Investor Conferences, Editas' SCD Candidate Gets FDA's Rare Pediatric Disease Tag, Editas Medicine Receives Rare Pediatric Disease Designation for EDIT-301 for the Treatment of Sickle Cell Disease, Editas' (EDIT) Earnings Beat in Q2, Revenues Improve Y/Y, Editas Medicine Announces Second Quarter 2020 Results and Update, Editas Medicine Regains Full Global Rights to Ocular Medicines, Editas Medicine Announces Closing of Offering of Common Stock and Full Exercise by Underwriter of Option to Purchase Additional Shares, Worldwide CRISPR Market to 2028 - Key Drivers, Restraints, Opportunities and Challenges, Editas Medicine Announces Pricing of Offering of Common Stock, Editas Medicine Announces Offering of Common Stock, First Week of February 2021 Options Trading For Editas Medicine.